What is the appropriate urgent evaluation and management for a 50-year-old woman presenting with sudden unilateral vision loss and a choroidal mass with surrounding subretinal fluid?

Urgent Ophthalmology Referral and Diagnostic Workup Required

A 50-year-old woman with sudden unilateral vision loss and a choroidal mass with surrounding fluid requires immediate same-day ophthalmology consultation to differentiate between life-threatening malignancies (choroidal melanoma, metastases) and treatable inflammatory conditions (posterior scleritis, sarcoidosis), as this presentation demands urgent multimodal imaging and potential systemic evaluation to prevent both vision loss and mortality from metastatic disease.

Critical Differential Diagnoses by Priority

The choroidal mass with subretinal fluid in this demographic carries a broad but finite differential that directly impacts both survival and vision outcomes:

Malignant Etiologies (Highest Mortality Risk)

• Choroidal melanoma: Most common primary intraocular malignancy; appears as hyperpigmented (or amelanotic) elevated mass with low internal reflectivity on ultrasound, multiple pinpoint leakage areas on fluorescein angiography (FA), and blockage on indocyanine green angiography (ICGA). Treatment ranges from brachytherapy to enucleation based on staging 111. Even in younger patients (30s), amelanotic variants can present with similar findings 2.

• Choroidal metastases: Yellow-white elevated lesions, potentially multifocal/bilateral, with high internal reflectivity on B-scan ultrasound. Critically, a minority of patients have no known primary tumor at presentation 11. Requires urgent systemic oncologic workup.

• Choroidal lymphoma: Presents in fifth-seventh decade with multifocal yellow-whitish infiltrates; demands thorough systemic screening for lymphoma 11.

Inflammatory Etiologies (Treatable, Vision-Salvageable)

• Posterior scleritis: Classic for middle-aged women presenting with deep pain, conjunctival hyperemia, painful eye movements, choroidal folds, and serous retinal detachment. Key diagnostic feature is fluid in sub-Tenon space (T-sign) on ultrasound with no leakage on FA/ICGA 111. Responds to corticosteroids and immunosuppression.

• Sarcoidosis: Choroidal granulomas with overlying subretinal fluid; may present as solitary mass mimicking tumor 3. One case report documented complete resolution with systemic steroids (vision improved from 20/50 to 20/20 over 2 months) after extensive workup including MRI, CT, colonoscopy, bone scintigraphy, and PET 3.

• Choroidal hemangioma: Elevated orange-red mass with mixed reflectivity on OCT, rapid vascular filling on ICGA with late wash-out phenomenon 11.

Immediate Diagnostic Algorithm

Step 1: Same-Day Ophthalmology Evaluation

The ophthalmologist must perform:

• B-scan ultrasonography: Differentiates solid masses (low reflectivity = melanoma; high reflectivity = metastasis; mixed = hemangioma; absent posterior echoes = osteoma) 111
• Optical coherence tomography (OCT): Characterizes subretinal fluid extent and mass architecture 4
• Fluorescein angiography (FA): Identifies leakage patterns (pinpoint in melanoma, diffuse in hemangioma, absent in posterior scleritis) 11
• Indocyanine green angiography (ICGA): Critical for distinguishing inflammatory (hyperfluorescence in posterior scleritis) from neoplastic (blockage in melanoma) lesions 11

Step 2: Risk Stratification for Malignancy

Proceed immediately to systemic workup if:

• Solid mass with low internal reflectivity on ultrasound (melanoma)
• High internal reflectivity on ultrasound (metastasis)
• Absence of pain/inflammation (tumors typically painless)
• Patient age 50+ (peak incidence for melanoma and metastases)

Consider inflammatory etiology if:

• Deep ocular pain with eye movement (posterior scleritis)
• T-sign on ultrasound with no FA/ICGA leakage (posterior scleritis)
• Systemic symptoms suggesting sarcoidosis/autoimmune disease

Step 3: Systemic Evaluation (When Malignancy Suspected)

For suspected melanoma or metastasis, urgent staging includes:

• MRI orbits with and without contrast (tumor characterization) 5
• CT chest/abdomen/pelvis (metastatic survey for primary tumor or melanoma staging)
• PET scan if lymphoma or metastasis suspected 3
• Liver function tests (melanoma metastasis screening)

For suspected inflammatory disease:

• Chest X-ray or CT chest (sarcoidosis, tuberculosis)
• ACE level, lysozyme (sarcoidosis)
• Tuberculin skin test or QuantiFERON (tuberculosis)
• ANA, RF, anti-dsDNA if systemic autoimmune disease suspected

Management Based on Diagnosis

If Choroidal Melanoma Confirmed:

Treatment depends on tumor size/location: brachytherapy, proton beam therapy, or enucleation 11. Anti-VEGF injections if neovascularization develops 1.

If Metastasis Confirmed:

Systemic chemotherapy, immunotherapy, hormone therapy, or whole-eye irradiation depending on primary tumor 11.

If Posterior Scleritis/Inflammatory:

High-dose corticosteroids (oral prednisone 1 mg/kg/day) with steroid-sparing immunosuppression if chronic 111. Vision recovery expected with prompt treatment.

If Sarcoidosis:

Systemic corticosteroids with monitoring for systemic disease progression; documented cases show excellent visual recovery 3.

Critical Pitfalls to Avoid

1. Delaying ophthalmology referral: Choroidal melanoma has significant metastatic potential; delayed diagnosis worsens mortality 2.

2. Assuming inflammatory cause without imaging: Inflammatory masses can spontaneously resolve 6, but failure to rule out malignancy is catastrophic. Always complete diagnostic workup even if symptoms improve.

3. Missing metastatic disease: Up to 50% of choroidal metastases present without known primary tumor 11. Systemic imaging is mandatory.

4. Treating empirically with steroids before diagnosis: If melanoma or metastasis, steroids delay definitive treatment without benefit. Secure tissue/imaging diagnosis first.

5. Inadequate imaging: B-scan ultrasound alone is insufficient. Multimodal imaging (OCT, FA, ICGA) is required to differentiate etiologies 115.

Prognosis and Follow-Up

• Melanoma: 5-year mortality from metastasis ranges 10-30% depending on size/location; early treatment improves outcomes
• Inflammatory disease: Excellent visual prognosis with prompt corticosteroid therapy 3
• Metastasis: Prognosis depends on primary tumor; ocular involvement often indicates advanced systemic disease

All patients require close ophthalmologic follow-up regardless of etiology, as complications (neovascularization, recurrence) can develop months to years later 11.